Results 121 to 130 of about 211,400 (307)

Longitudinal genome‐wide aneuploidy measurements in circulating cell‐free DNA to predict lack of benefit from pembrolizumab in patients with metastatic urothelial cancer

Molecular Oncology, EarlyView.
Many patients with urothelial cancer do not benefit from treatment with pembrolizumab, while at risk of severe side effects. Changes in the levels of circulating tumor DNA early during treatment, measured by a simple and affordable assay that can be easily implemented in the clinic, can be used as a prognostic tool to identify these patients.
Youssra Salhi, Stavros Makrodimitris, Sandra van Wilpe, Iris te Paske, Vanja de Weerd, Corine M. Beaufort, Hans M. Westgeest, Jens Voortman, Maureen J. B. Aarts, Maud Rijnders, Astrid A. M. van der Veldt, Ronald de Wit, Niven Mehra, Saskia M. Wilting, Debbie G. J. Robbrecht   +14 more
wiley   +1 more source

Modelling drug coatings: A parallel cellular automata model of ethylcellulose-coated microspheres [PDF]

, 2011
Pharmaceutical companies today face a growing demand for more complex drug designs. In the past few decades, a number of probabilistic models have been developed, with the aim of improving insight on microscopic features of these complex designs.
Crane, Martin, Martin Crane, Marija Bezbradica, Heather J. Ruskin, Ruskin, Heather J., Bezbradica, Marija   +5 more
core  

Transporting silence: Design of carriers for siRNA to angiogenic endothelium

, 2005
The recently developed siRNA oligonucleotides are an attractive alternative to antisense as a therapeutic modality because of their robust, gene selective silencing of drug target protein expression.
Zhou, Q., Scaria, PV, Molema, G; id_orcid, Molema, G., Advanced drug delivery systems/drug targeting, Tang, QQ, Scaria, P.V., Zhou, Q, Lu, PY, Dep Farmaceutische wetenschappen, Mixson, A.J., Xu, J., Storm, G, Mixson, AJ, Fens, MHAM, Ansari, A.M., Tang, Q., Schiffelers, R.M., Ansari, AM, Woodle, M.C., Storm, G., Dep Biologie, Universiteit Utrecht, Woodle, MC, Molema, G, Fens, M.H.A.M., Lu, P.Y.   +26 more
core   +1 more source

MITF maintains genome stability in nonmelanocyte lineages

Molecular Oncology, EarlyView.
MITF is essential for melanocyte survival and acts as an oncogene in 10%–20% of melanomas. We show that MITF depletion causes genome instability in nonmelanocytic cells, leading to LATS2‐mediated P53 activation, cell cycle arrest, and apoptosis. This study highlights the role of MITF as a genome maintenance factor beyond the melanocyte lineage. Created
Drifa H. Gudmundsdottir, Adrián López García de Lomana, Thejus B. Venkatesh, Kritika Kirty, Snaevar Sigurdsson, Linda Vidarsdottir, Ramile Dilshat, Erla Sveinbjornsdottir, Snaedis Ragnarsdottir, Daniel H Magnusson, Maria R. Bustos, Eirikur Steingrimsson, Thorkell Gudjonsson, Stefan Sigurdsson   +13 more
wiley   +1 more source

drug carrier

Citation: 'drug carrier' in the IUPAC Compendium of Chemical Terminology, 5th ed.; International Union of Pure and Applied Chemistry; 2025. Online version 5.0.0, 2025. 10.1351/goldbook.13931 • License: The IUPAC Gold Book is licensed under Creative Commons Attribution-ShareAlike CC BY-SA 4.0 International for individual terms.
openaire   +1 more source

Vesicular carriers for dermal drug delivery

, 2009
The skin can offer several advantages as a route of drug administration although its barrier nature makes it difficult for most drugs to penetrate into and permeate through it. During the past decades there has been a lot of interest in lipid vesicles as
FADDA, ANNA MARIA, Sinico C
core   +1 more source

A double‐edged sword: The complex interplay between engineered nanoparticles and platelets

Bioengineering & Translational Medicine
Nanoparticles (NP) play a crucial role in nanomedicine, serving as carriers for localized therapeutics to allow for precise drug delivery to specific disease sites and conditions.
Yathreb Asaad, Danielle Nemcovsky‐Amar, Josué Sznitman, Pierre H. Mangin, Netanel Korin   +4 more
doaj   +1 more source

A novel quinazolinone insulin receptor inhibitor and its synergy with an EGFR inhibitor in glucose‐driven glioblastoma

Molecular Oncology, EarlyView.
The novel styrylquinazolinone‐based molecule W1B effectively suppresses glioblastoma by inhibiting IGF1R and EGFR. In high‐glucose microenvironments driving tumor resistance, W1B acts synergistically with the EGFR inhibitor dacomitinib. This combination safely blocks compensatory survival signaling in zebrafish xenograft models. Showcasing promising in
Patryk Rurka, Wioleta Cieślik, Wojciech Płaziński, Katarzyna Stępnik, Anna Boguszewska‐Czubara, Elżbieta Kot, Robert Musioł, Mateusz Jasica, Anna Mrozek‐Wilczkiewicz, Katarzyna Malarz   +9 more
wiley   +1 more source

Multimetal organic frameworks as drug carriers: aceclofenac as a drug candidate

, 2018
Muder Al Haydar,1,2 Hussein Rasool Abid,3,4 Bruce Sunderland,5 Shaobin Wang6 1Pharmaceutics Department, College of Pharmacy, University of Kerbala, Kerbala, Iraq; 2Pharmaceutics Department, School of Pharmacy, Faculty of Health Sciences, Curtin ...
Al Haydar M, Wang S, Sunderland B, Abid HR   +3 more
core  

Exploring Protein-Based Carriers in Drug Delivery: A Review

Drug delivery systems (DDSs) represent an emerging focus for many researchers and they are becoming progressively crucial in the development of new treatments.
Francesco Patitucci, Sabrina Prete, Ortensia Parisi, Giuseppe Scopelliti, Francesco Puoci, Marco Dattilo, Claudia Ferraro   +6 more
core   +1 more source